Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
Crohn’s and Colitis 2025 Advance Access: 13 July 2025 Doi: 10.1093/ecco-jcc/jjaf124
Mirikizumab was evaluated for its ability to achieve disease clearance (DC) across two years in adults with moderately to severely active ulcerative colitis within the LUCENT trial programme. DC required concurrent symptomatic, endoscopic, and histologic remission.
Mirikizumab improved DC versus placebo at Wk12 and Wk52, with approximately half of mirikizumab-treated clinical responders achieving DC by Wk104. DC was achieved in both bio-naïve and bio-failed patients and was associated with greater improvements in fatigue, HRQoL, functioning, and PROs. Early DC predicted more favourable long-term outcomes, supporting the value of early deep response.
Keywords:
